Fast, Affordable Biosecurity for Livestock and Food Production
Avicena Sentinel enables rapid, high-volume detection of animal pathogens — helping producers, exporters, and governments contain outbreaks before they devastate herds, trade, or food security.
Global trade, climate pressures, and increased movement of animals are raising the risk of infectious disease outbreaks.
Diseases such as Lumpy Skin Disease, African Swine Fever, and Avian Flu pose significant threats to livestock, food supply chains, and national economies.
In a high-stakes industry, early detection is everything, and traditional diagnostics can’t keep up.
Diagnostic Solution
a. Dewhurst, R.E., Heinrich, T., Watt, P. et al. Validation of a rapid, saliva-based, and ultra-sensitive SARS-CoV-2 screening system for pandemic-scale infection surveillance. Sci Rep 12, 5936 (2022). https://doi.org/10.1038/s41598-022-08263-4.
Get accurate results in under 30 minutes with throughput of 10 to 5,000 tests per hour. Continuously loaded, no batching.
Screen at any scale with affordable per-test costs and minimal manual handling, even in high-volume settings.
Sentinel instruments can deploy at livestock yards, border posts, farms, or mobile units, with no cold chain or complex infrastructure.
Enable early intervention, reduce culling, and safeguard animal trade with timely data.
Sentinel platforms support a wide range of sample types, including saliva, nasal, blood, and skin lesions.
Each sample is collected in a barcoded tube pre-filled with stabilising buffer, enabling secure, end-to-end tracking from collection to result.
Avicena’s end-to-end sample collection software integrates with RFID readers, QR-code or text-based consignment tracking systems for fast and seamless tracking.
Avian influenza (AI), also known as Bird Flu, is a viral disease that affects birds worldwide. There are many strains of the virus, the most severe causing deadly infections in poultry.
Bird species, from chickens to ducks, and livestock and cats are vulnerable to Avian flu, with over 140 species reported as carriers.
In 2022, 67 countries in five continents reported [high pathogenicity avian flu] outbreaks… with more than 131 million domestic poultry lost due to death or culling.
Lumpy Skin Disease Virus (LSDV) is an imminent threat to Australia’s livestock industry.
The temporary suspension of some Australian cattle imports due to the virus underscores the potentially severe economic impact of such an outbreak.
An outbreak of [LSDV] would cost Australia $7.4 billion in its first year, from lost trading opportunities.
Avicena’s end-to-end diagnostic system empowers animal health teams to detect and respond fast — with flexible sample handling, scalable throughput, and secure reporting for traceability and biosecurity compliance.
Sentinel supports rapid, high-accuracy testing for a range of notable and economically significant animal diseases, including:
Custom assay development is also available for region-specific pathogens or emerging threats.
Traditional testing often requires samples to be sent to central labs, with results delayed by days.
Sentinel enables on-site or near-site molecular diagnostics with PCR-grade accuracy, delivering results in under 30 minutes. It reduces outbreak response time from days to hours, which can be the difference between containment and spread.
Yes. The Sentinel Mini, when combined with the Seguro module, is designed for rugged and remote deployment.
Sentinel supports a variety of sample types including:
Sampling protocols can be adapted based on species and disease type.
Sentinel provides PCR-comparable accuracy and includes internal quality controls for each run. The system has been validated in laboratory and field conditions, and our mobile workflows are designed to ensure sample integrity, reproducibility, and compliance.
Yes. The Sentinel platform is ISO 13485 certified, CE-marked for IVD, and built according to regulatory standards for molecular diagnostics. Each test assay must be approved by relevant local regulatory authorities for diagnostic use.
ISO 13485 certified for the design, development, and manufacture of in vitro diagnostics
CE-Marked for use in the in vitro diagnostic (IVD) molecular testing
Avicena holds several patent pending innovations that enable our groundbreaking performance.
Validation of a rapid, saliva-based, and ultra-sensitive SARS-CoV-2 screening system for pandemic-scale infection surveillance. Dewhurst RE, et al. 2022. Nature, Scientific Reports.
